Timely treatment with COVID-19 monoclonal antibodies can reduce hospitalizations, pandemic’s stress on health care systems

Monoclonal antibodies work well in reducing COVID-19 related emergency department visits and hospitalizations when administered early to high-risk patients, a study demonstrates. If used under FDA guidelines, the researchers suggest, this treatment can ease the pandemic’s continuing burden on patients and on limited health care resources.